News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘ProstateCancer’ clear

  • Dana-Farber researchers have demonstrated that a hormone-depleting drug can help eliminate or nearly eliminate aggressive prostate cancers that have yet to spread beyond the prostate.

Tags: Hormones, ProstateCancer, TranslationalResearch

  • A new SU2C and Prostate Cancer Foundation Dream Team, dedicated to advanced prostate cancer research, includes two Dana-Farber researchers among scientists from leading prostate cancer centers in the U.S. and England.

Tags: ProstateCancer

  • Hormone-blocking therapy for prostate cancer doesn’t raise the risk of fatal heart attacks - as some recent studies had suggested - according to a new report from Dana-Farber/Brigham and Women’s Cancer Center.

Tags: Hormones, ProstateCancer

  • Dr. Philip Kantoff says the United States Preventive Services Task Force's conclusion that prostate-specific antigen (PSA) testing provides limited value is the wrong message.

Tags: ProstateCancer

  • New research from the Dana-Farber/Brigham and Women's Cancer Center shows that newer, more expensive treatment options for prostate cancer were adopted rapidly and widely during 2002–2005 without proof of their cost-effectiveness.

Tags: ProstateCancer

  • Researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease.

Tags: Genomics, ProstateCancer

  • Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, Dana-Farber Cancer Institute researchers report in an online study published by the journal Nature.

Tags: ProstateCancer, Genetics

  • Analysis finds higher quality of life for men diagnosed with low-risk prostate cancer who choose ongoing exams over immediate treatment.

Tags: ProstateCancer

  • The FDA's approval of Provenge®, a prostate cancer vaccine, marks a new era of using patients' immune systems to treat cancer.

Tags: ImmuneSystem, ProstateCancer, TranslationalResearch, Immunotherapy

  • The vaccine, which contained weakened poxviruses genetically programmed to spur an immune system attack on prostate tumor cells, helped patients lived longer than patients who received a placebo vaccine.

Tags: ProstateCancer, TranslationalResearch

Showing 11-20 of 26 items